The Neurohacker Collective contends that nootropics are largely presented in a reductionist model and have historically lacked a general sense of safety, preventing new consumers from entering the biohacker space. We talked to CEO James Schmachtenberger about these and other challenges facing the science and the category at large.

Read the full article: The brand that's finally making nootropics go mainstream